Tempus AI, Inc. (NASDAQ:TEM) is one of them ARK Investment Stock Portfolio: Top 10 Stock Picks for 2026. On March 3, the company announced a strategic partnership with Merck to accelerate AI-driven precision medicine development and support the drugmaker’s oncology portfolio and other therapeutic offerings.
As part of the agreement, Merck will acquire Tempus AI, Inc. (NASDAQ:TEM) leverages Unidentified Data and the Lens platform and workspace technologies to make new discoveries and accelerate the development and effective use of candidate therapies on a large scale.
In other news, on February 25, JPMorgan analyst Casey Woodring lowered the stock’s price target to $60 from $80, with a neutral rating, following the company’s Q4 earnings a day earlier.
Image from Iovance Biotherapeutics website
According to TipRanks, the company Tempus AI, Inc. (NASDAQ:TEM) cited a ‘clouded outlook’ on the upside of the data and a revision to its outlook for Embry as the reason for the adjustment.
As of the close of business on March 4, the stock is a moderate buy, with an average upside probability of 52.5%.
Tempus AI, Inc. (NASDAQ:TEM) is a healthcare technology company that uses artificial intelligence to advance precision medicine.
While we acknowledge the potential of TEM as an investment, we believe that some AI stocks offer higher potential and lower risk. If you’re looking for the most undervalued AI stocks that stand to benefit significantly from Trump-era tariffs and the offshore trend, check out our free report Best short-term AI stocks.
Read more: 40 Most Popular Stocks Among Hedge Funds Heading into 2026 and 10 Best Magic Formula Stocks for 2026.
Disclosure: None. Follow the inside port on Google News.
